CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior

CD98hc (SLC3A2) regulation of skin homeostasis wanes with age

(2013) Etienne Boulter et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

(2012) B Beuselinck et al.   BRITISH JOURNAL OF CANCER

Activity of Single-Agent Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

(2012) James D. Turnbull et al.   Clinical Genitourinary Cancer

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Renal cell carcinoma

(2010) Brian I Rini et al.   CURRENT OPINION IN ONCOLOGY

CD98hc (SLC3A2), a novel marker in renal cell cancer

(2009) G. W. Prager et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc,SLC3A2)

(2009) Per Fogelstrand et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Renal cell carcinoma

(2008) P. F. A. Mulders   WORLD JOURNAL OF UROLOGY